Journal
/
/
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
JoVE Journal
Cancer Research
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Cancer Research
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
DOI:

09:38 min

June 26, 2019

, , , ,

Chapters

  • 00:04Title
  • 00:38Initial Afatinib PC-9 Cell Exposure Determination by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) Assay
  • 01:46Continuous Afatinib Exposure
  • 03:01PC-9 Cell Growth Curve Determination
  • 03:46Epidermal Growth Factor Receptor (EGFR) Genomic DNA Alteration Evaluation
  • 04:53Epidermal Growth Factor Receptor (EGFR) Protein Alteration Evaluation
  • 07:39Results: Afatinib-resistant Cell Characterization
  • 08:59Conclusion

Summary

Automatic Translation

A method for establishing afatinib-resistance cell lines from lung adenocarcinoma PC-9 cells was developed, and resistant cells were characterized. The resistant cells can be used to investigate epidermal growth factor receptor tyrosine kinase inhibitor-resistance mechanisms, applicable for patients with non-small cell lung cancer.

Related Videos

Read Article